Biotech | March 14, 2026
MetaVia locks down global patent shield for metabolic drug candidate Vanoglipel
The protections extend through at least 2035, with the potential for further extensions
The protections extend through at least 2035, with the potential for further extensions
Marks significant milestone for breakthrough biologic to treat rare blood cancers
The new facilities are designed to provide focused, patient-centric care through advanced diagnostics, minimally invasive treatments, and multidisciplinary expertise
The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
Giredestrant shows promise despite missing primary goal
Subscribe To Our Newsletter & Stay Updated
